Fibrocell Technologies, Inc.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Fibrocell Technologies, Inc..The latest application filed is for "treatment of vocal cords with autologous dermal fibroblast formulation".

Company Profile

3.13.18

Fibrocell Technologies, Inc. - Exton PA US
Fibrocell Technologies, Inc. -

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks

Patent Activity

Patent	Date
Treatment Of Vocal Cords With Autologous Dermal Fibroblast Formulation App 20210299183 - Maslowski; John	2021-09-30
Methods for culturing minimally-passaged fibroblasts and uses thereof Grant 10,900,020 - Maslowski , et al. January 26, 2	2021-01-26
Treatment of vocal cords with autologous dermal fibroblast formulation Grant 10,881,695 - Maslowski January 5, 2	2021-01-05
Treatment Of Vocal Cords With Autologous Dermal Fibroblast Formulation App 20190151368 - Maslowski; John	2019-05-23
Methods For Culturing Minimally-Passaged Fibroblasts And Uses Thereof App 20180346878 - Maslowski; John ; et al.	2018-12-06
Treatment of vocal cords with autologous dermal fibroblast formulation Grant 10,098,914 - Maslowski October 16, 2	2018-10-16
Methods for culturing minimally-passaged fibroblasts and uses thereof Grant 9,902,937 - Maslowski , et al. February 27, 2	2018-02-27
Treatment Of Vocal Cords With Autologous Dermal Fibroblast Formulation App 20170035811 - Maslowski; John	2017-02-09
Methods For Culturing Dermal Cells For Treatment Of Skin Injuries Such As Burns App 20160340651 - Maslowski; John ; et al.	2016-11-24
Treatment of vocal cords with autologous dermal fibroblast formulation Grant 9,415,075 - Maslowski August 16, 2	2016-08-16
Treatment of Vocal Cords With Autologous Dermal Fibroblast Formulation App 20140348801 - Maslowski; John	2014-11-27
Methods For Culturing Minimally-Passaged Fibroblasts And Uses Thereof App 20140335057 - Maslowski; John ; et al.	2014-11-13
Treatment of vocal cords with autologous dermal fibroblast formulation Grant 8,765,121 - Maslowski July 1, 2	2014-07-01
Methods for culturing minimally-passaged fibroblasts and uses thereof Grant 8,728,819 - Maslowski , et al. May 20, 2	2014-05-20
Topical Dermal Formulations App 20140099383 - Maslowski; John M. ; et al.	2014-04-10
Methods and Compositions for Treating Post-Cardial Infarction Damage App 20140072611 - Maslowski; John M.	2014-03-13
Dosage Unit Formulations of Autologous Dermal Fibroblasts App 20130295061 - Maslowski; John M.	2013-11-07
Topical Dermal Formulations and Methods of Personalized Treatment of Skin App 20130236427 - Pernock; David M.	2013-09-12
Dosage unit formulations of autologous dermal fibroblasts Grant 8,529,883 - Maslowski September 10, 2	2013-09-10
Treatment of Vocal Cords with Autologous Dermal Fibroblast Formulation App 20130224160 - Maslowski; John	2013-08-29
Topical Dermal Formulations App 20120219634 - Maslowski; John M. ; et al.	2012-08-30

Company Registrations

NCAGE Code	62F16	FIBROCELL TECHNOLOGIES, INC.
CAGE Code	62F16	FIBROCELL TECHNOLOGIES, INC.
S.A.M. Registration	62F16 [67980859]	FIBROCELL TECHNOLOGIES, INC.
DUNS	067980859	FIBROCELL TECHNOLOGIES, INC.

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.